Loading
Pulmonary Disease, Chronic Obstructive / Asthma / Lung Diseases · Journal article
Gut Microbes · June 21, 2026
Raises a question worth testing. It does not answer one.
This narrative review proposes an integrative cross-kingdom framework linking gut mycobiome, virome, bacteriophages, and bacteria to respiratory disease susceptibility and outcomes via the gut-lung axis. The authors explicitly acknowledge the framework is an organizing construct rather than a validated model, derived largely from murine or reductionist studies with limited human causal evidence.
Journal article. Patients with asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome, and lung cancer.
Review integrates bacteria, fungi, and virome/phageome into cross-kingdom framework for gut-lung axis. Framework centered on PAMP-PRR circuits, SCFA-regulatory T-cell axis, and tryptophan-indole-AHR signaling. Authors compare perturbations across asthma, COPD, ARDS, and lung cancer as non-sequential disease contexts.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The framework offers a conceptual scaffold for interpreting how gut microbiome interventions—dietary modulation, prebiotics, probiotics, postbiotics, and phage-based strategies—might refine prevention and adjunctive treatment in selected respiratory contexts. Clinicians should recognize this represents hypothesis-generating synthesis rather than actionable clinical evidence, with causal validation in humans still needed.
Narrative review synthesizing mechanistic frameworks for cross-kingdom gut-lung microbiome interactions without presenting new experimental data or clinical evidence.
As stated by the source record.
The framework offers a conceptual scaffold for interpreting how gut microbiome interventions—dietary modulation, prebiotics, probiotics, postbiotics, and phage-based strategies—might refine prevention and adjunctive treatment in selected respiratory contexts. Clinicians should recognize this represents hypothesis-generating synthesis rather than actionable clinical evidence, with causal validation in humans still needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cross-kingdom dysbiosis of the gut microbiome along the gut-lung axis has emerged as a key driver of chronic and acute respiratory diseases. Beyond bacteria, the intestinal mycobiome and virome, including bacteriophages, shape mucosal immunity and metabolism through partially overlapping but non-redundant pathways. In this Review, we synthesize rapidly expanding evidence that fungi, bacteria, and phages in the gut form an integrated network that may influence susceptibility, inflammatory tone, and therapeutic responsiveness across asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and lung cancer via the gut-lung axis. We first summarize how cross-kingdom communities in the intestine are organized and interact, highlighting a tripartite framework centered on pathogen-associated molecular pattern-pattern recognition receptor (PAMP-PRR) circuits, the short-chain fatty acid (SCFA)-regulatory T-cell axis, and tryptophan-indole-aryl hydrocarbon receptor (AHR) signaling. We then compare how these shared axes are differentially perturbed across asthma, COPD, ARDS, and lung cancer, using these disorders as representative but non-sequential disease contexts along a conceptual gradient of immune-microecological disruption. Finally, we discuss how dietary modulation, pre-/pro-/postbiotics, mycobiome- and virome-targeted strategies, and phage-based approaches could be rationally combined to restore gut-derived immunometabolic circuits and improve respiratory outcomes. By integrating cross-kingdom ecology with mucosal immunology, this Review provides an integrative interpretive framework suggesting that gut microbiome-targeted strategies may help refine prevention, stratification, and adjunctive treatment approaches in selected respiratory disease contexts.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.